Parexel will tap into real-world data to connect the biopharmaceutical services provider to data from the company’s clinical trials through a multi-year partnership with Bay Area-based Datavant.
Syapse, which accelerates precision medicine through insights derived from the company’s global health system network, announced a strategic collaboration with Pfizer Inc. to advance cancer outcomes research using real-world evidence toward the ultimate goal of improving patient health.
Clinical-stage immuno-oncology company Forty Seven Inc. announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence.
A recent report written by SVB Leerink analysts that looked at eight companies and their research-and-development portfolios found that in the past five years, they progressed only 24 percent of their new molecular entities to approval.
Eisai Co. Ltd. initiated Phase 3 clinical trials of the Alzheimer’s treatment BAN2401 one day after the Japanese drugmaker and U.S. partner Biogen Inc. scrapped studies for the Alzheimer’s drug aducanumab.
Boehringer Ingelheim announced a 230 million euro investment into a new biologicals development center at the company’s research and development site in Biberach, Germany.
Conference to Be Held May 19-23, 2018 in Baltimore, MD, USA Lawrenceville, NJ, USA—May 9, 2018—ISPOR, the professional society for health economics and outcomes research, released the final program and […]
According to the consultants at PwC, the top health industry issues of 2018 will be …
